###### Strengths and limitations of this study

-   The internal and external validity of findings were strengthened by use of standardised data available over a long time horizon and for a geographically-defined population covered by a universal health system.

-   By applying novel time-series analyses we demonstrated population interactions, strain-competition and non-linear relationships with ecological determinants, convergent with understandings of the emergence and spread of resistance.

-   An observational and ecological study design meant that associations may have been due to unidentified confounding variables, and may not have captured variation in molecular epidemiology explained by individual-level exposures.

Introduction {#s1}
============

*Staphylococcus aureus* colonises around a third of humans, and is an important cause of infections in both hospital and community.[@R1] Resistance to penicillinase-resistant penicillins was first recognised more than 50 years ago,[@R2] and today methicillin-resistant *S. aureus* (MRSA) is among the most commonly identified resistant nosocomial infections worldwide.[@R3] Resistance to β-lactam antibiotics is conferred by acquisition of a mobile genetic element: the *Staphylococcal* cassette chromosome (SCC*mec*).[@R4] This section of DNA contains the *mecA* gene, encoding for a modified penicillin binding protein; cassette chromosome recombinase genes, allowing for its excision and horizontal transfer; and variable elements encoding additional antibiotic resistances.[@R5] [@R6] Rapid adaptation to selective pressures within a clonal genomic background facilitates clonal expansion and diversification, and this biodiversity allows MRSA to occupy a range of ecological niches.[@R7] Hospital-associated (HA-) strains typically contain SCC*mec* types I--III, encoding resistance to multiple antibiotics but also associated with slower growth and reduced toxin expression.[@R5] This fitness burden means HA-MRSA strains are typically limited to contexts of high-antibiotic pressure and high density of vulnerable hosts. Community-associated (CA-) MRSA strains are characterised by SSC*mec* types IV--XI, carrying variable resistance to antibiotics and small fitness burdens.[@R5] [@R8] These strains have a fitness advantage where selective pressures of antibiotic use fall below critical levels, and can infect healthy populations. Interactions of strains in hospital and community are increasingly recognised.[@R7] [@R9] [@R10] The hospital epidemic strain EMRSA-15 is SSC*mec* IV, retaining some features consistent with its origin in the community.

The complex and evolving MRSA population structure creates challenges in the design and evaluation of control measures.[@R11] In the UK, national initiatives of infection control and antibiotic stewardship have been linked to a declining MRSA epidemic.[@R12] However, intervention effects may be strain-specific: the offset of fitness advantage and antibiotic resistance suggests that modifying ecological pressures could lead to clonal replacement.[@R10] [@R11] [@R15] Wyllie *et al*[@R16] [@R17] have even suggested that declines in MRSA are attributable to spontaneous evolution within the MRSA population rather than impacts of infection control, and that health systems will continue to ride 'waves of trouble'.

The ability to identify MRSA strains by molecular typing provides a tool for mapping their evolution and spread, and may inform more effective control strategies.[@R18] European studies have linked strain dominance to clinical context and antibiotic use,[@R15] [@R19] [@R20] with a particular focus on fluoroquinolones.[@R10] [@R21] Advanced time-series analysis is well suited to investigating evolution in MRSA population structure, since it can distinguish the intrinsic progression of naturally occurring time series from external influences of changes in ecological pressures.[@R24] While such analyses have explored associations between infection control measures and total MRSA rates,[@R25] we are not aware of any previous application to strain dynamics. Mathematical models have suggested critical thresholds in the impacts of ecological pressures, such as total antibiotic use, on resistance,[@R30] [@R31] but to date empirical studies have only defined linear associations.

In this intervention study we used non-linear time-series analysis to investigate the extent to which national antibiotic stewardship and infection control strategies have determined the molecular epidemiology of MRSA across a Scottish health board between January 1997 and December 2012.

Methods {#s2}
=======

Study design {#s2a}
------------

This retrospective observational study explored temporal associations between clinical burdens from MRSA clonal complexes and recent ecological exposures. Strain distribution and exposures were measured at monthly intervals over 16 years. This time frame reflected the availability of routine typing data and covered a period of emergence, stabilisation and decline in MRSA. It also allowed evaluation of the impacts of national infection control and antibiotic stewardship strategies, prompted by detection of high rates of nosocomial infection in mandatory surveillance. Analysis controlled for natural progression within time series of MRSA strain, strain competition and interactions between different clinical populations.

Setting and population {#s2b}
----------------------

*NHS Grampian* is a large health board, serving 11% of Scotland\'s population. We investigated strain dynamics in three care settings: primary care (*community*), and general surgical/medical wards (*hospital*) or intensive care units (*ICU*) of the 1000-bed regional referral hospital---Aberdeen Royal Infirmary (ARI). Less than 5% of admissions are transferred from other hospitals or regions. See [table 1](#BMJOPEN2014006596TB1){ref-type="table"} for further details of participants.

###### 

Study overview according to the ORION statement[@R32]

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Setting*: Community, hospital and intensive care unit (ICU) settings in North East Scotland**.** Infection prevention and control team (IPCT) including 1 WTE ICD; 8 WTE ICNs; 1.84 WTE antibiotic pharmacists; regional antibiotic management team (AMT)   *Dates*: 1 January 1997--31 December 2012 (192 months)                                                                                                                                                                                                                                      *Population*: 480 000 adults registered in primary care; 1 091 250 admissions to general medical/surgical wards and 19 279 admissions to intensive care wards of Aberdeen Royal Infirmary (ARI). Mean (SD) age, 56 (1.2). Median (IQR) length-of-stay: 3.7 (3.5--4.1)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Mean (SD) MRSA prevalence density in hospital and community=1.91 (1.06)/1000 OBDs and 0.024 (0.017)/10 000 Inhabitant-days

  Antibiotic stewardship policy                                                                                                                                                                                                                                *January 1997 to April 2009*: Annual reviews of hospital empirical antibiotic therapy guidelines. Very limited restrictive policies in place. Ongoing efforts to limit use of macrolides since January 2008\                                                                                
                                                                                                                                                                                                                                                               *May 2009 to December 2012*: Empirical guidelines recommended regimens avoiding '4C' antibiotics (Coamoxiclav, cephalosporins, ciprofloxacin (all quinolones), clindamycin). Restricted supply of these antibiotics with use requiring prior authorisation from microbiology and pharmacy   

  General infection control measures                                                                                                                                                                                                                           Alcohol gel introduced (November 2002)                                                                                                                                                                                                                                                      

  National hand-hygiene campaign (January 2007)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  National auditing of environmental cleaning (April 2006)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Healthcare Environment Inspectorate (HIE) inspection (January 2010)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  MRSA admission screening                                                                                                                                                                                                                                     Intensive Care Unit (ICU) Admission screening (May 2001)                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                               Selective screening elective surgery and HDU (January 2006)                                                                                                                                                                                                                                 

  Universal admission screening (August 2008 to March 2011)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Targeted admission screening (March 2011 onwards)†                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Isolation and eradication policy                                                                                                                                                                                                                             Isolation (single-room) or cohorting of all patients with known MRSA or MRSA infected /colonised at admission\                                                                                                                                                                              
                                                                                                                                                                                                                                                               Decolonisation of all MRSA-positive patients with 5 days chlorhexidine body washes and intra-nasal mupirocin                                                                                                                                                                                

  Definitions and outcomes                                                                                                                                                                                                                                     Hospital-associated (HA-) MRSA cases                                                                                                                                                                                                                                                        Non-duplicate MRSA isolates (1 per 14 days) from clinical specimens taken \>48 h after admission to hospital or ICU, excluding screening and infection control swabs

  Community-associated (CA-) MRSA case                                                                                                                                                                                                                         Non-duplicate MRSA isolates from clinical specimens taken in the community or \<48 h of admission to hospital, excluding screening or infection control swabs                                                                                                                               

  Colonisation at admission                                                                                                                                                                                                                                    Isolation of MRSA from ≥1 admission screening swab, or known previous MRSA                                                                                                                                                                                                                  

  HA- or CA-MRSA Clonal Complex prevalence density                                                                                                                                                                                                             Hospital- or community-associated cases of MRSA attributable to a given clonal complex per 1000 OBDs (Hospital) or per 10 000 inhabitant-days (Community)                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

†Recommended as a minimum standard by NHS Scotland following results of pathfinder study.[@R25]

ICD, infection control doctor; ICN, infection control nurse; MRSA, methicillin resistant *S. aureus;* NHS, National Health Service; OBDs, occupied bed days; WTE, whole time equivalents.

Outcomes and exposures {#s2c}
----------------------

The primary outcomes for the study were hospital-associated and community-associated prevalence densities of infections (de-duplicate clinical isolates) involving major clonal complexes grouped as CC22; CC30; and CC5/other strains. Data on prior healthcare exposures were not available so CA-MRSA included infections described elsewhere as healthcare associated.

We considered a number of ecological exposures previously associated with MRSA burdens. Monthly population antibiotic use was measured in defined daily doses (DDDs)/1000 occupied bed days (OBDs) in hospital, or DDDs/1000 inhabitant-days (IDs) in the community, and summarised according to the WHO Anatomical Therapeutic Chemical (WHO/ATC) classification.[@R33] Other covariates included: MRSA admission screening intensity (admissions screened/1000 OBDs); total and strain-specific importation pressures (admissions colonised or previous MRSA/1000 OBDs); mean length of stay (days) and bed-occupancy (%) in hospital populations. Consistent data on alcohol gel consumption and preintervention adherence with hand hygiene or environmental cleaning standards were not available. We therefore introduced instrumental variables coding for changes in level (0 prior, 1 during intervention) and trend (autoregression×intervention) in strain prevalence densities associated with start of intervention.

Data collection {#s2d}
---------------

Typing and antibiotic resistance phenotype data were derived from the Scottish MRSA Reference Laboratory (SMRSARL) for 10 707 MRSA clinical isolates and 4273 MRSA admission screening specimens from non-duplicate cases. Total antibiotic consumption in primary care was derived from the Prescribing Information System for Scotland (PRISMS). Remaining data was retrieved from regional health intelligence, pharmacy, microbiology and infection control departments. Any individual or specimen level data were pseudoanonymised by removal of identifiable personal information and replacement of unique personal or specimen numbers with matched study codes.

Laboratory methods {#s2e}
------------------

All *S. aureus* isolates were identified by agglutination, mainly with the Prolex-- Blue Staph Latex Kit (Pro-Lab). Antibiograms were determined using Clinical and Laboratory Standards Institute agar disk diffusion methods and, from 2008, by a Vitek instrument, using custom made *Staphylococcus* sensitivity cards (Biomerieux). EUCAST interpretative criteria were used from January 2012. MRSA screening swabs were cultured on MRSA selective medium, with use of chromogenic agar (Brilliance---Oxoid, UK) from 2006. Further details of methods utilised in the study period are available from previous publications.[@R25] [@R29] All first patient clinical and screening isolates per year were sent to the reference lab until March 2011, after which only isolates from screening, blood cultures, outbreak investigations, or with unusual phenotypes were referred. Epidemiological typing of MRSA isolates into clonal complex was based on a combination of genotypic and phenotypic characteristics, matching \>90% to known strains. Isolates were typed by the methods in use at the reference laboratory at the time of receipt. These varied during this study but always involved at least two independent methods. All isolates had their antibiotic resistance profile and biotype determined and at least one of phage typing, pulsed-field gel electrophoresis (PFGE), PCR-ribotyping or spa typing was also performed. If the resistance pattern or biotype was not one commonly associated in Scotland with the determined lineage then additional typing methods (usually multilocus sequence typing, MLST) were used or, rarely, the strain was designated 'Other'. This means that, despite the multiplicity of typing methods used during the period of the study, there is high confidence in the typing result for those isolates ascribed to a specific lineage. No isolate was assigned to a lineage based on its antibiotic resistance profile alone. Assignment to a sublineage was based on antibiotic resistance profile or SCC*mec* typing by PCR.

Statistical analysis {#s2f}
--------------------

Temporal trends in MRSA clonal complexes were estimated by applying the strain distributions (% typed isolates belonging to each clonal complex) to the total MRSA prevalence density in the same month in each clinical population. The distribution of antibiotic resistance phenotypes and sublineages by strain and quarter of year were summarised by heat-maps after excluding those appearing in ≤5 isolates in the study period. Autoregressive Integrated Moving Average (ARIMA) models were generated to explore temporal associations between hospital consumption of macrolides, ciprofloxacin and clindamycin and associated resistances (% isolates) in each MRSA strain.[@R24]

To investigate the dissemination of clonal complexes through the regional healthcare network we considered temporal associations between strain prevalence density in ICU, hospital and community and among those colonised with MRSA at admission. Granger causality tests were used to identify the direction of possible relationships (at lags 1--3 months). Long-run associations between time-series were defined by the Johansen cointegration test, and used to inform a Vector Error Correction model (lags 1--3 months) incorporating cointegration equations. Path diagrams were generated based on significant associations in these models, with connecting arrows proportional to the percentage of total variation in prevalence density explained by variation in other populations.

Finally, we used non-linear time-series analysis to explore significant predictors of strain prevalence density in hospital (full details are provided in online supplementary file 1). Potentially significant non-linear associations were identified from visual inspection of the output from Generalised Additive Models (GAM). Candidate variables were entered into Multivariate Adaptive Regression Spline (MARS) models defining associations as a series of linear segments across ranges of the independent variables separated by thresholds (knots). Analyses were performed using SPSS V.21.0 (IBM), Eviews V.8.0 (IHS, California, USA) and SCA V.8.1 (Scientific Computing Associates Corp, Illinois, USA).

Results {#s3}
=======

Trends in MRSA clonal complexes {#s3a}
-------------------------------

Information on epidemiological typing was available for 60% (n=4597/7727) of clinical isolates in the hospital population, 74% (5651/7647) of isolates in the community and 80% (459/573) in the ICU ([figure 1](#BMJOPEN2014006596F1){ref-type="fig"}A). Applying strain distributions ([figure 1](#BMJOPEN2014006596F1){ref-type="fig"}B) to the total MRSA prevalence densities in each population provided estimates of strain-specific prevalence densities ([figure 1](#BMJOPEN2014006596F1){ref-type="fig"}C).

![(A) Epidemiological typing of clinical MRSA isolates, and distribution of clonal complexes† as (B) cumulative per cent typed isolates or (C) prevalence density by population. †'Other' clonal complexes included CC7, CC15, CC59, CC88, CC93 and C239; ‡Cases/1000 OBDs (hospital) or Cases/10 000 IDs (community); §Estimated by applying % strain distribution (B) to population MRSA prevalence densities (A).](bmjopen2014006596f01){#BMJOPEN2014006596F1}

A consistent secular trend in strain distribution was seen across all three populations. Between 1997 and 2003 CC30 (mostly UK-EMRSA-16) was the dominant strain. High prevalence densities of CC30 were seen in ICU before introduction of MRSA admission screening in this unit (May 2001), with little presence in the community. Between 2004 and 2008 the dominant strains were CC22 (UK-EMRSA-15) and, to a lesser extent, CC45 (limited to our region in Scotland), with large clinical burdens in all settings. Finally, from 2008 there was greater strain diversity, with CC5, CC8, CC1 and other clonal complexes of increasing importance. These strains explained 30% of HA-MRSA and 50% of CA-MRSA by 2012.

Trends in antibiotic resistance phenotypes and sublineages {#s3b}
----------------------------------------------------------

Excluding resistance phenotypes represented by ≤5 isolates over the study period, MRSA isolates could be explained by 37 antibiograms ([figure 2](#BMJOPEN2014006596F2){ref-type="fig"}). Ninety-four per cent of CC30 and 90% of CC45 isolates were resistant to erythromycin, ciprofloxacin and clindamycin, and 78% of CC22 were characterised by resistance to erythromycin and ciprofloxacin. By contrast 92% of CC5 were susceptible to all three agents. Multidrug resistance (≥3 antibiotic classes) was present in 88% (95% CI, 87% to 90%) of isolates before the third quarter of 2008, declining sharply thereafter to 60% (57% to 63%). Multidrug resistance in CC22, increased from 6% when CC30 was dominant to 57% when CC22 was dominant (2004--2008), falling to 25% during antibiotic stewardship; Kruskal-Wallis test, p=0.002. The most commonly acquired resistances in CC22 included trimethoprim (4% increasing to 66%; p\<0.001), tetracycline (1.4% to 10.7%; p\<0.001), clindamycin (1.3% to 3.9%); p\<0.001 for all comparisons. Concurrent increases in trimethoprim resistance were observed in CC30 (0.7% to 7.3%; p\<0.001), but not CC5/other strains (10.5% to 4.8%; p=0.058).

![Heat map of antibiotic resistance phenotypes including total number in study period, percentage of isolates in each strain and percentage of all isolates per quarter of year.](bmjopen2014006596f02){#BMJOPEN2014006596F2}

Changes in antibiotic resistance phenotypes of prevalent strains were predicted by trends in antibiotic consumption. During antibiotic stewardship resistance to erythromycin, ciprofloxacin and clindamycin declined in all strains ([table 2](#BMJOPEN2014006596TB2){ref-type="table"} and [figure 3](#BMJOPEN2014006596F3){ref-type="fig"}).

###### 

Temporal associations between hospital use of macrolides, fluoroquinolones and clindamycin and related antibiotic resistances within strains

  Antibiotic and strain                        ARIMA model\* (p,d,q) (P,D,Q)   Model R^2^   Lag   Coefficient (95% CI)†    T ratio   p Value
  -------------------------------------------- ------------------------------- ------------ ----- ------------------------ --------- ---------
  Macrolide use, DDDs/1000 OBDs                                                                                                      
   CC22, % erythromycin resistance             (1,0,1) (1,0,0)                 0.291        0     0.088 (0.012 to 0.164)   2.25      0.026
   CC30, % erythromycin resistance             (2,0,2) (0,0,0)                 0.432        5     0.098 (0.006 to 0.190)   2.08      0.039
   CC5 and other, % erythromycin resistance    (1,0,0) (0,0,0)                 0.109        0     0.110 (0.090 to 0.130)   11.51     \<0.001
  Fluoroquinolone use, DDDs/1000 OBDs                                                                                                
   CC22, % ciprofloxacin resistance            (2,0,2) (1,0,0)                 0.451        0     0.062 (0.027 to 0.097)   3.36      0.001
   CC30, % ciprofloxacin resistance            (2,0,2) (1,0,0)                 0.331        0     0.128 (0.048 to 0.209)   3.14      0.002
   CC5 and other, % ciprofloxacin resistance   (1,0,2) (0,0,0)                 0.074        0     0.108 (0.076 to 0.140)   6.58      \<0.001
  Clindamycin use, DDDs/1000 OBDs                                                                                                    
   CC22, % clindamycin resistance              (1,0,1) (0,0,0)                 0.298        0     0.173 (0.137 to 0.208)   9.76      \<0.001
   CC30, % clindamycin resistance              (2,0,1) (0,0,0)                 0.691        0     0.455 (0.067 to 0.843)   2.30      0.023
   CC5 and other, % clindamycin resistance     (2,0,1) (0,0,0)                 0.176        0     0.334 (0.175 to 0.493)   4.11      \<0.001

\*Autoregressive Integrated Moving Average models, in which: p=order (number) of non-seasonal autoregressive terms representing impact of previous values in time-series, d=order of differencing to achieve stationary time-series; q=order of non-seasonal moving average terms representing response to previous disturbances (residual error) in time-series; and P, D, Q reflect orders of seasonal (lag 12) autoregressive, differencing and moving average terms.

†Change in % resistance associated with a +1 DDD/1000 OBDs increase in antibiotic use.

DDDs, defined daily doses; OBDs, occupied bed days.

![Percentage of isolates within strains resistant to erythromycin, ciprofloxacin or clindamycin and consumption of related antibiotics from univariate ARIMA time-series models (3 m moving averages).](bmjopen2014006596f03){#BMJOPEN2014006596F3}

Changes in antibiotic resistance phenotypes within strains were partially explained by shifts in the distribution of sublineages ([figure 4](#BMJOPEN2014006596F4){ref-type="fig"}). Before antibiotic stewardship, hospital epidemic strains were dominated by sublineages with high rates of resistance to ciprofloxacin, erythromycin and clindamycin, including ST22-MRSA-IV (E15), ST36-MRSA-II (E16) and ST45-MRSA-II. During antibiotic stewardship higher proportions of isolates within these strains were from alternative sublineages, characterised by much lower rates of resistance to these three antibiotics. Conversely, within strains dominated by sublineages with low rates of resistance (including CC5 and CC8), alternative and more resistant sublineages, such as SM119, Tayside E3 and CC5-II, declined during antibiotic stewardship. One exception was the increasing importance within CC8 of Panton-Valentine Leukocidin (PVL) positive isolates, resembling USA300.[@R6]

![Heat map describing relative frequency (percentage of total isolates in strain per quarter) of sublineages of the five most prevalent clonal complexes.](bmjopen2014006596f04){#BMJOPEN2014006596F4}

Interactions of MRSA population structure in different populations {#s3c}
------------------------------------------------------------------

Typing was available for 33% (4273/13 048) of non-duplicate MRSA admission screening isolates. Applying the strain distribution from this typing to the total MRSA positive admission swabs per month provided time-series for strain-specific importation pressures for general hospital and ICU environments. Trends in strain-specific importation pressures coincided with the strain dynamics seen among clinical isolates.

Granger causality tests and Vector Error Correction (VEC) models confirmed significant temporal associations between prevalence density of strains in ICU, hospital and community populations and strain-specific importations pressures ([figure 5](#BMJOPEN2014006596F5){ref-type="fig"}). Importation pressures followed trends in related hospital prevalence densities, with less consistent and sizeable associations with community or ICU trends. Community prevalence densities of CC22, CC30 and CC45 were strongly determined by prior rates in hospital and ICU. By contrast, hospital epidemiology of CC5/other was anticipated by rates in the community.

![Flow charts of temporal associations between prevalence density of MRSA strains in different clinical populations, as derived from Vector Error Correction (VEC) models. Boxes represent patient populations, arrows the direction of temporal association and numbers (months) the delay in associated changes. Arrow width is proportional to the percentage of total variation in response time-series (population prevalence density) explained by input time-series.](bmjopen2014006596f05){#BMJOPEN2014006596F5}

Multivariate time series analyses {#s3d}
---------------------------------

MARS models explained 91%, 94% and 58% of variation in prevalence densities of CC22, CC30 and CC5/other strains, respectively ([table 3](#BMJOPEN2014006596TB3){ref-type="table"}).

###### 

Summary of time series multivariate adapative regression splines models

  Explanatory variables (order of terms)              Lag (months)   Threshold†   Relation to threshold   Change in prevalence density (95% CI)   T-ratio   p Value
  --------------------------------------------------- -------------- ------------ ----------------------- --------------------------------------- --------- ---------
  \(a\) CC22 (R^2^=0.912)                                                                                                                                   
   AR (1)                                             1              1.06         Above                   +0.474 (0.271 to 0.677)                 +4.57     \<0.001
   AR (2)                                             1              2.18         Above                   −0.530 (−0.941 to −0.119)               −2.52     0.023
   CC30 prevalence density, cases/1000 OBDs           0              0.363        Above                   −0.337 (−0.483 to −0.231)               −6.26     \<0.001
   Mean bed-occupancy, %                              3              78.4         Above                   +0.022 (0.006 to 0.038)                 +2.66     0.017
   Mean length of stay, days                          2              4.06         Above                   +0.694 (0.178 to 1.210)                 +2.63     0.018
   Hand-hygiene campaign×AR (1), trend effect         6              0.26         Above                   −0.143 (−0.231 to −0.055)               −3.16     0.006
   Admissions screened for MRSA/1000 OBDs (1)         1              4.24         Above                   +0.138 (0.088 to 0.188)                 +5.38     \<0.001
   Admissions screened for MRSA/1000 OBDs (2)         1              7.87         Above                   −0.137 (−0.188 to −0.086)               −5.26     \<0.001
   Admissions screened for MRSA/1000 OBDs (3)         1              69.7         Above                   −0.007 (−0.012 to −0.002)               −2.42     0.028
   MRSA+at admission/1000 OBDs                        0              0.145        Above                   +0.178 (0.125 to 0.231)                 +6.53     \<0.001
   Fluoroquinolone use, DDDs/1000 OBDs (1)            2              78.6         Above                   +0.033 (0.009 to 0.057)                 +2.69     0.016
   Fluoroquinolone use, DDDs/1000 OBDs (2)            2              72.8         Above                   −0.032 (−0.055 to −0.009)               −2.62     0.019
   Macrolide use, DDDs/1000 OBDs                      1              135          Above                   +0.009 (0.002 to 0.015)                 +2.62     0.019
   Coamoxiclav use, DDDs/1000 OBDs                    2              235          Above                   +0.010 (0.004 to 0.016)                 +3.10     0.007
   Third Gen. Cephalosporin use, DDDs/1000 OBDs       5              81.0         Below                   −0.007 (−0.010 to −0.004)               −4.22     \<0.001
  \(b\) CC30 (R^2^=0.940)                                                                                                                                   
   AR (1)                                             1              1.189        Above                   +6.40 (4.48 to 8.311)                   +6.54     \<0.001
   AR (2)                                             1              1.273        Above                   −6.62 (−8.85 to −4.40)                  −5.84     \<0.001
   AR (3)                                             1              1.773        Above                   +0.794 (0.240 to 1.349)                 +2.80     0.010
   CC22 prevalence density, cases/1000 OBDs (1)       0              0.157        Below                   +4.34 (2.99 to 5.71)                    +6.28     \<0.001
   CC22 prevalence density, cases/1000 OBDs (2)       0              0.157        Above                   −0.207 (−0.288 to −0.126)               −5.01     \<0.001
   Mean bed-occupancy, %                              1              73.7         Above                   +0.021 (0.009 to 0.033)                 +3.50     0.002
   Mean length of stay, days                          1              3.85         Above                   +0.531 (0.274 to 0.787)                 +4.05     \<0.001
   Admissions screened for MRSA/1000 OBDs             1              5.11         Above                   −0.007 (−0.008 to −0.005)               −8.92     \<0.001
   MRSA+ at admission/1000 OBDs (1)                   0              0.498        Below                   −2.442 (−3.382 to −1.501)               −2.91     0.008
   MRSA+ at admission/1000 OBDs (2)                   0              0.498        Above                   −2.492 (−4.596 to −1.247)               −2.91     0.008
   MRSA+at admission/1000 OBDs (3)                    0              0.623        Above                   +2.86 (1.15 to 4.56)                    +3.27     0.003
   MRSA+at admission/1000 OBDs (4)                    0              3.038        Above                   −0.361 (−0.464 to −258)                 −6.86     \<0001
   Fluoroquinolone use, DDDs/1000 OBDs (1)            4              49.4         Below                   −0.049 (−0.071 to −0.027)               −4.38     \<0.001
   Fluoroquinolone use, DDDs/1000 OBDs (2)            4              49.4         Above                   +0.018 (0.017 to 0.019)                 +3.92     \<0.001
   Fluoroquinolone use, DDDs/1000 OBDs (3)            4              67.3         Above                   −0.021 (−0.031 to −0.011)               −4.16     \<0.001
   Macrolide use, DDDs/1000 OBDs                      1              141          Above                   +0.022 (0.016 to 0.028)                 +7.05     \<0.001
   Coamoxiclav use, DDDs/1000 OBDs                    5              160          Below                   −0.005 (−0.008 to −0.002)               −3.35     0.003
   Coamoxiclav use, DDDs/1000 OBDs                    5              160          Above                   −0.003 (−0.005 to −0.001)               −3.82     \<0.001
   Third gen. Cephalosporin use, DDDs/1000 OBDs       5              71.9         Below                   −0.008 (−0.013 to −0.003)               −3.74     0.001
  \(c\) CC5/Other strains (R^2^=0.583)                                                                                                                      
   AR (1)                                             2              0.166        Below                   −0.314 (−0.575 to -0.05)                −2.35     0.018
   AR (2)                                             2              0.166        Above                   −0.22 (−0.370 to −0.070)                −2.87     0.007
   AR (3)                                             1              0.273        Above                   −0.457 (−0.657 to −0.257)               −4.47     \<0.001
   Mean length of stay, days                          1              3.98         Below                   +0.177 (0.097 to 0.257)                 +4.33     \<0.001
   Admissions screened for MRSA/1000 OBDs (per 10+)   0              110          Above                   −0.011 (0.005 to 0.017)                 −3.10     0.005
   MRSA+ at admission/1000 OBDs (1)                   3              4.565        Above                   +0.041 (0.012 to 0.070)                 +2.87     0.007
   MRSA+ at admission/1000 OBDs (2)                   5              6.235        Below                   +0.184 (0.170 to 0.198)                 +2.49     0.014
   MRSA+ at admission/1000 OBDs (3)                   5              6.235        Above                   +0.971 (0.908 to 1.033)                 +3.50     0.002
   Macrolide use, DDDs/1000 OBDs                      5              141          Above                   +0.005 (0.002 to 0.008)                 +3.59     0.002
   Coamoxiclav use, DDDs/1000 OBDs                    5              241          Above                   +0.008 (0.005 to 0.013)                 +6.07     \<0.001
   Third gen. Cephalosporin use, DDDs/1000 OBDs       5              47.1         Below                   −0.004 (−0.006 to −0.002)               −3.69     \<0.001

†Level of explanatory variable at which association appears.

AR, autoregressive term, reflecting impact of previous prevalence density in the same strain; DDDs, defined daily doses; MRSA, methicillin resistance *Staphylococcus aureus;* OBDs, occupied bed days.

Prevalence densities of CC22 and CC30 were inversely related suggesting competition for the same ecological niche. Bed occupancies above 74 to 78% and length-of-stay over 4 days, were associated with higher rates of CC22 and CC30 over the next 1 to 3 months (lags 1--3) ([figure 6](#BMJOPEN2014006596F6){ref-type="fig"}). The negative coefficient for the interaction term hand hygiene×AR (1) suggests the hand-hygiene campaign exerted a downward pressure on CC22 strongest in months of high prevalence density (where values of AR (1) were high). No association was noted with CC30 prevalence density which was already low at initiation of the campaign. In contrast, rates of CC5/other strains increased when length-of-stay was \<4 days and were not related to hand hygiene or bed occupancy.

![Contribution charts illustrating non-linear associations between explanatory variables and prevalence density of CC22, CC30, CC5/other strains. Lines represent the change in (Δ) prevalence density (y axis) associated with changes in explanatory variables over their observed range (see boxplots). Thresholds ('knots') are represented by a change in direction in the line. Where y=0 there is no association with the explanatory variable. A dotted line represents an area of uncertainty within which the actual threshold is likely to be located.](bmjopen2014006596f06){#BMJOPEN2014006596F6}

Importation pressure was important in determining nosocomial rates of CC22 and CC30 at almost all levels, whereas association with CC5/other strains was mostly at high importation pressures (\>6.24 MRSA+ admissions/1000 OBDs). Increased intensity of MRSA admission screening was followed by declines in prevalence density of CC30, CC22 and CC5/other beyond thresholds of 5, 70 and 110 admissions screened per 1000 OBDs, respectively. The difference in threshold reflected the influence of earlier ICU screening on CC30, when overall inpatient screening levels were low.

Consistent non-linear associations were seen between inpatient macrolide or third generation cephalosporin use and prevalence density of all strains ([figure 6](#BMJOPEN2014006596F6){ref-type="fig"}). Macrolide consumption was positively associated with rates of CC30, CC22 and CC5, above a total use threshold of 125--141 DDDs/1000 OBDs. A 'ceiling' effect was noted for all associations with third generation cephalosporin use, with reductions in consumption below 71--81 DDDs/1000 OBDs associated with lower prevalence densities, but no relationship seen above this threshold. A threshold effect was also observed with coamoxiclav use above 235--241 DDDs/1000 OBDs being followed by similar increases in CC22 and CC5/other prevalence density, but a positive association with CC30 was only seen at lower levels of consumption (up to 160 DDDs/1000 OBDs).

Other strain-specific associations reflected the resistance phenotype of the strain. Clindamycin consumption above 25 DDDs/1000 OBDs was positively associated with rates of CC30, but was not significantly related to CC22 or CC5/other strains at any level of use. Increases in CC30 prevalence density were seen at levels of fluoroquinolone use up to 68 DDDs/1000 OBDs (lag 4). Consumption above this level was inversely associated with CC30 but positively associated with CC22, suggesting selective advantage of CC22 under higher antibiotic pressure.

Where antibiotic consumption was positively associated with strain prevalence density, the median (range) percentage isolates within strains with related resistances was 98.1% (40--100%), compared to 3.7% (3.5--32%) where no association was identified (Mann-Whitney U test, p=0.004). Consumption of other antibiotics in hospital or community were not significantly related to strain dynamics.

Discussion {#s4}
==========

This 16-year retrospective study represents the first ever application of non-linear time-series analysis to investigate ecological determinants of MRSA strain dynamics. Following recent declines in hospital-associated epidemic strains such as CC22 and CC30, clonal complexes arising from the community, including CC5, became increasingly important in the region. Large shifts in strain distribution were underpinned by more subtle changes in sublineages and antibiotic phenotypes associated with changes in selective pressure from antibiotic use. Even after accounting for interactions between clinical populations, and natural progression within time series, we demonstrated that changes in infection control and antibiotic use were important predictors of this evolving MRSA population structure. Improved hand hygiene, and reductions in bed occupancy or length of stay, were followed by declining inpatient burdens from HA epidemic strains but had little or opposite effects on community strains. The HA prevalence density of all clonal complexes declined with increasing intensity of admission screening, but thresholds for association were strain specific. Responses to consumption of antibiotics reflected the resistance phenotype of the strain and were subject to total use thresholds.

This study had several limitations. An observational and ecological design meant that associations may not be causal, may be explained by unidentified confounding variables, and may not reflect variation in molecular epidemiology due to individual-level exposures. However, although retrospective in nature, use of routinely collected data from electronic databases and standardised microbiological[@R34] and clinical definitions minimised risks of information bias. Change in criteria for sending isolates for typing (March 2011) was not likely to introduce bias since: major changes in antibiotic use and infection control occurred before this time, and covariates and direction of associations in baseline models for months before were unchanged; time series for strain distribution derived from isolate types sent throughout the study period were strongly correlated with time series derived from wider range of isolates typed before the change in criteria (R^2^ for 5-month moving averages=0.85--0.96). Use of a long-time series (N=192) and restriction of candidate explanatory variables through two-step GAM and MARS procedures helped to reduce the potential for spurious (chance) associations. Nevertheless measures of uncertainty around associations may be underestimated where data are used for model estimation and hypothesis testing. Further applications of our approach to other, similar, data sets is required to validate parameters reported here. Between 6% and 42% of variation in strain prevalence densities was not explained by multivariate models, suggesting unidentified determinants. We were unable to obtain consistent data on: staffing-levels;[@R35] transfer-rates;[@R23] isolation and decolonisation performance;[@R36] and compliance with hand hygiene and environmental cleaning before initiation of national strategies.[@R37] External validity was strengthened by exploring strain dynamics in a geographically-defined population covered by a universal health system, and in various levels of care. However, our findings also highlight the importance of healthcare environments and local ecological exposures in shaping strain dynamics, which may limit generalisability of specific associations.

Previous evidence on associations between infection control measures or antibiotic use and MRSA strain-dynamics has largely been from in vitro or animal experiments,[@R21] [@R38] and mathematical models.[@R39] While such studies have demonstrated important concepts of stain competition and strain-specific impacts of manipulating selective pressures, examining the evolution of MRSA in real-life contexts provides greater ecological and population validity. Wyllie *et al*[@R16] have highlighted the importance of considering internal strain-dynamics when evaluating the contribution of national infection control strategies to recent declines in MRSA within the UK. In a large observational study, these authors explored the evolution of MRSA and two epidemic strains (CC30 and CC22) in Oxfordshire hospitals alongside infection control strategies.[@R17] They concluded that recent falls in MRSA rates were more likely attributable to spontaneous strain dynamics than interventions since: declines were seen before intensification of infection control; and decline in CC30 was much steeper than that in CC22. Elsewhere, in a 10-year study of an MRSA population in a London hospital, Knight *et al*[@R22] noted a similar shift in dominant strain from CC30 to CC22, and attributed it to fitness advantage in CC22 after acquisition of additional resistances. This evolution was independent of ecological pressures, but fluoroquinolone resistance was a key feature of successful hospital strains and overall MRSA declined after restriction of these antibiotics. These investigations made limited attempts to model impacts of interventions and changing antibiotic use, adjust for expected progression of time series, or consider population interactions. In overcoming these methodological weaknesses, our study helps reconcile conflicting evidence.

First, results of multivariate models suggest that even those infection control measures expected to have general effects can have strain-specific impacts due to differences in the temporal and spatial distribution of clonal complexes. Threshold effects of hand hygiene have been identified previously.[@R40] Our findings also suggest that impacts of a national initiative to improve hand hygiene were dependent on background prevalence densities of CC22 and CC30 during the campaign.[@R40] Greater impact during period of high prevalence density is consistent with the role of hand hygiene in reducing transmission, and of diminishing returns at lower prevalence density.[@R41] Several time-series analyses have demonstrated the importance of bed occupancy in determining rates of MRSA,[@R42] with both guidelines[@R43] and research[@R35] suggesting safety thresholds between 82 and 90%. We found highly consistent associations between bed occupancy and rates of CC22 and CC30 above thresholds of 74--78%: much lower than average bed occupancies of 82--88% across the UK.[@R44] The association with bed occupancy was not explained by variation in mean inpatient age and seasonality, but may reflect changes in case-mix during winter rather than increased transmission. Congruent with hospital burdens from CC5/other strains being driven by importation from the community, no associations were seen with hand hygiene or bed occupancy. Similarly while lower average length of stay anticipated declines in CC22 and CC30, it was associated with increases in hospital burdens from CC5/other strains. Given that antibiotic-resistant infections lead to longer length of stay a complex bidirectional relationship is likely.[@R45] We noted the threshold of hospital-wide MRSA admission screening at which declines were seen varied considerably between strains, probably reflecting the roll-out among different clinical populations, and background rates of strains.[@R46] Population interaction models suggested that ICU was a key environmental niche for CC30, consistent with a highly drug resistance phenotype. Early introduction of admission screening in this unit (May 2001) resulted in an abrupt and permanent decline in total MRSA rates,[@R47] which this study suggests was attributable to control of CC30. Responsiveness may also reflect much more frequent carriage of qacA, encoding for chlorhexidine resistance, in CC22 compared to CC30.[@R48] However, we have not identified increasing chlorhexidine resistance in the ICU. Declines in CC22 and CC5/other strains were limited to months when hospital-wide screening exceeded 70 and 110 admissions screens/1000 OBDs: a level only seen during expansion to high-dependence unit/surgical and universal admission screening, respectively. On the basis of cost-effectiveness,[@R49] risk-factor-based (targeted) screening is advocated in Scotland. However, since community strains can appear in patients without traditional risk-factors for MRSA, this approach may be insufficient to prevent invasion into hospitals.[@R50]

We further demonstrated the importance of selective pressures from population antibiotic use in determining the molecular epidemiology of MRSA. Alongside non-linear associations strongly related to the typical resistance profiles of strains, declining use of '4C' and macrolide antibiotics coincided with changes in antibiotic resistance phenotypes and shift towards more susceptible sublineages within all clonal complexes. Total antibiotic use thresholds may represent 'tipping points' at which ability to adapt to different selective pressure determines strain success within environmental niches. The rapidity of change within strains during hospital antibiotic stewardship is in keeping with mathematical models demonstrating declines in resistance within weeks to months, even in the absence of high fitness costs.[@R31] [@R51] Studies in France have described secular trends towards strains and resistance phenotypes with susceptibility to macrolides and gentamicin despite a lack of change in antibiotic consumption.[@R15] [@R19] However, use of macrolides in these areas was around 40 DDDs/1000 OBDs, and well below the thresholds for association with strain prevalence in our study. The studies also highlighted the selective advantage of strains carrying SCC type IV, associated with high genetic plasticity mediated by the frequent transfer of[@R42] mobile genetic elements.[@R15] Consistent with Knight *et al*[@R22] we noted that dominance of CC22-IV in hospital coincided with acquisition of multiple antibiotic resistances. We have previously noted increasing trimethoprim resistance in major epidemic strains associated with regional use in MRSA throat decolonisation.[@R52] Our finding that CC22 outcompeted CC30 at higher intensity of fluoroquinolone (FQ) use is congruent with lower fitness costs of FQ resistance in CC22,[@R21] and its critical role in the dissemination of CC22 through the UK health system.[@R23]

Our findings suggest that implementation and evaluation of interventions to control MRSA can be improved by consideration of non-linear and strain-specific impacts. Recognising critical thresholds in modifiable ecological pressures may enhance cost-effectiveness by determining optimal levels of intervention and identifying areas where impacts are unlikely.[@R53] Limiting population antibiotic use to below critical levels may provide a powerful means to balance immediate clinical need with avoidance of resistance and sustainability of use.[@R30] Further applications of our approach in other populations and clinical contexts is required to elucidate factors modifying thresholds for association with ecological variables, and to adapt antibiotic stewardship or infection control policies to local scenarios. These factors may include: age and comorbidities in the clinical population; baseline rates of MRSA; existing strain distributions; importation pressures;[@R50] and interactions with other populations.[@R23] Previous investigations have demonstrated complex within-host strain dynamics. Multilevel analyses could quantify the relative contribution of individual and population level exposures to acquisition or infection with specific strains.[@R54] The relative weakness of existing hospital-based infection control measures in controlling CC5/other strains seen in this study suggests a pressing need for strategies to control burdens from clonal complexes arising in the community.[@R55]

In conclusion, this study found evidence that changes in infection control and population antibiotic use have contributed to MRSA strain dynamics in Scotland over the past 16 years. Declines in overall clinical burdens from MRSA were convergent with intensified hospital infection control and antibiotic stewardship strategies removing selective pressures favouring hospital epidemic strains. Future efforts to control MRSA, and in particular evolving community strains, should consider thresholds for effects and strain-specific impacts.
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